SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

Aspirin vs Clopidogrel: Scoping Review with ☸️SAIMSARA.

Cardiac & Vascular Health icon

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsara2e3a8ec9

Editorial note
• Last update: 2026-04-15 21:27:28
What is this paper about
This review shows where clopidogrel truly outperforms aspirin, where the advantage disappears, and why the answer changes across PCI, stroke, PAD, gastrointestinal risk, and surgery. It turns a common everyday antiplatelet choice into a clinically practical evidence map of who may benefit more from clopidogrel, when aspirin may still be safer, and where the real uncertainties remain.
Found an issue in this paper? Email admin@saimsara.com


Abstract: To synthesize the evidence comparing the efficacy and safety of aspirin and clopidogrel across diverse clinical settings, including coronary artery disease (CAD), ischemic stroke, peripheral artery disease (PAD), and perioperative management. The review utilises 2319 original studies with 9103381 total participants (topic deduplicated ΣN). The mapped evidence suggests that clopidogrel monotherapy is a prominent long-term alternative to aspirin, with the clearest advantage appearing after percutaneous coronary intervention and in broad symptomatic atherosclerotic disease, where reported hazard ratios ranged from 0.71 to 0.86 in post-percutaneous coronary intervention maintenance studies and CAPRIE reported an annual risk of 5.32% versus 5.83%, corresponding to an 8.7% relative risk reduction. This signal was not uniform across all settings: stroke cohorts were mixed, and the apparent benefit of clopidogrel was repeatedly modified by high on-treatment platelet reactivity and CYP2C19 loss-of-function status. Safety patterns were similarly context dependent, with clopidogrel often appearing less injurious to the upper gastrointestinal tract in general-risk settings, yet aspirin plus esomeprazole outperforming clopidogrel alone after prior aspirin-related ulcer bleeding, and perioperative bleeding concerns more often favoring aspirin when procedures cannot be delayed. Clinically, the evidence map supports a role for clopidogrel as a preferred single antiplatelet option after the dual antiplatelet phase following percutaneous coronary intervention, while also highlighting the need to individualize treatment according to gastrointestinal history, surgical plans, and likely clopidogrel responsiveness. Future research should prioritize indication-specific prospective comparisons, especially in heterogeneous stroke populations and very elderly patients, with integrated genotype-guided strategies to clarify who benefits most from aspirin versus clopidogrel.

Keywords: Antiplatelet monotherapy; Ischemic stroke; Secondary prevention; Myocardial infarction; Gastrointestinal bleeding; Percutaneous coronary intervention; Platelet reactivity; CYP2C19 polymorphism; Vascular events; Dual antiplatelet therapy

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (116)
Article views: —
Follow us

© 2026 SAIMSARA Journal Impressum Published by ML in Health Science GbR